Request A Quote
Home  /  News

Blood Center Leukocyte Filtration Program

Apr. 02, 2019

Safety, timeliness and effectiveness are the principles of clinical blood transfusion. With the progress of science and technology and the improvement of people's living standards, people pay more attention to blood quality, and have higher requirements on blood quality, blood transfusion efficacy and blood transfusion safety.

Scientific studies have shown that Leukocyte Filtration can reduce the incidence of non-hemolytic transfusion fever and post-transfusion graft-versus-host disease (GVHD), prevent partial transfusion-related virus infection, and prevent ineffective platelet transfusion caused by HLA alloimmune response. For this reason, the blood center decided to use special filter bags to collect blood for the first trial, so as to prepare the blood products such as white blood cells and suspension red blood cells for clinical use, marking the official start of the center's blood white blood cell filtration project.

Link: WBC Filter suspension products for: 1. Patients with adverse transfusion reactions such as fever due to leukocyte antibodies produced by blood transfusion; 2. Blood transfusions that prevent the production of leukocyte antibodies (such as in organ transplant patients) have the same ABO blood group as the recipients. Patients preparing for organ transplantation; Patients who need repeated transfusions, such as those with aplastic anemia, leukaemia and thalassemia major, may choose this product from the first transfusion.

                                                Leukocyte Filtration



contact us
  • Jack Wang
  • Tel. no.: +86 20 32167473 Fax no.: +86 20 32167642
  • Mob. No.: +86 138 0888 4077
  • WeChat: wxid_1qg0hytucabc22    Skype: 13808884077
  • Email: daji@dajimed.com
daji Medical

2F No.132 Buling Road HuangPu District GuangZhou, GuangDong, Province, P.R.CHINA

follow us

Request A Quote